InvestorsHub Logo
Followers 0
Posts 161
Boards Moderated 0
Alias Born 03/31/2014

Re: gi197845 post# 605

Tuesday, 09/08/2020 3:53:11 PM

Tuesday, September 08, 2020 3:53:11 PM

Post# of 785
Well, that would certainly be better than another CRL. I don't see Clarus' exclusivity being an issue. I believe Tlando being fixed dose while Jatenzo requires titration will be the difference. That's just my opinion. Jatenzo's exclusivity is based on the following taking from the Exclusivity Summary (link below):

https://www.fda.gov/media/138223/download

The determination is consistent with FDA’s decision to recognize exclusivity for other testosterone replacement therapies that have received exclusivity in the past based on the same general study design (a phase 3 study with a primary efficacy endpoint of the proportion of treated subjects with a T Cavg within the normal range after dose titration was complete).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LPCN News